BPC-157 + TB-500 Stack
Also known as: Wolverine Stack, Healing Stack, BPC-TB combo
Overview
The BPC-157 + TB-500 combination, sometimes called the 'Wolverine Stack,' is one of the most studied and widely referenced peptide synergy protocols in the research community. The two peptides have complementary and largely non-overlapping mechanisms—BPC-157 acts primarily on local tissue repair via VEGF/FAK signaling while TB-500 mobilizes systemic stem cell populations and actin cytoskeletal repair. Used together, they address healing from multiple angles: inflammatory modulation, vascularization, stem cell recruitment, connective tissue synthesis, and neurological repair.
Mechanism of Action
BPC-157 contributes: VEGFR2/Akt/eNOS-mediated angiogenesis at injury sites, FAK-paxillin fibroblast migration, cytoprotection via NO system and PGE2 modulation, and gut-brain axis support via serotonin/dopamine balance. TB-500 (Thymosin Beta-4) contributes: G-actin sequestration enabling cell migration and proliferation, SDF-1α/CXCR4-mediated stem cell mobilization to injury sites, VEGF-A upregulation for new blood vessel formation, and anti-inflammatory NF-κB inhibition. The combination addresses the full tissue repair cascade from initial inflammatory response through vascularization to connective tissue remodeling.
Potential Benefits
- Synergistic tissue repair exceeding either compound alone
- Complementary mechanisms: local (BPC-157) and systemic (TB-500) healing
- Accelerated tendon, ligament, and muscle recovery
- Enhanced angiogenesis at injury sites
- Neurological repair component from both peptides
Dosage Protocols
The following reflects doses used in published research studies. This is not medical advice. Consult a qualified healthcare professional.
| Beginner | BPC-157 250 mcg/day + TB-500 2 mg 2x/week for 4 weeks |
| Intermediate | BPC-157 500 mcg/day + TB-500 5 mg 2x/week for 4-6 weeks |
| Advanced | BPC-157 500 mcg/day SC + 250 mcg IM near injury + TB-500 5 mg 2x/week for 8 weeks |
| Cycle Duration | 4-8 weeks (loading) then 2-4 week maintenance or off |
Gold-standard healing/recovery stack. BPC-157 promotes angiogenesis + GI protection; TB-500 promotes actin mobilization and systemic tissue remodeling.
Use our Reconstitution Calculator to determine exact syringe units for your protocol.
Routes of Administration
Subcutaneous Injection High
Standard route for both peptides in the stack.
Intramuscular Injection High
Preferred for injury-site targeting (tendon, joint, muscle).
Read our full Routes of Administration Guide for detailed comparison of all delivery methods.
Stacking Protocols
Popular research stacks involving BPC-157 + TB-500 Stack:
Extended Recovery Stack
Adds GHK-Cu for ECM remodeling and angiogenesis support.
Injury + GH Axis Stack
Layered healing plus endogenous GH/IGF-1 elevation for connective tissue repair.
Explore our complete Peptide Stacking Guide for more combinations and safety considerations.
Reconstitution
| Storage | Refrigerate at 2-8°C after reconstitution. Do not freeze reconstituted solution. |
|---|
Typical vial sizes: BPC-157 5 mg + TB-500 5 mg vials. Add bac water slowly down the side of the vial, swirl gently — do not shake. Use insulin syringe for precise dosing.
Need exact syringe measurements?
Amino Acid Sequence
See individual BPC-157 and TB-500 entries
Side Effects & Safety
- See individual BPC-157 and TB-500 entries
- Combination safety: no formal evaluation
Safety & Contraindications
This information is for educational purposes only. Consult a qualified healthcare provider before using any peptide.
Pregnancy / Lactation
Bleeding Disorders
Active Skin Infection at Injection Site
Pharmacokinetics
| Half-Life | BPC-157: ~4 h; TB-500: ~2-3 h (both have longer biological effects than plasma half-life suggests) |
|---|---|
| Storage | Store lyophilized peptide at -20°C (long-term) or 2-8°C (short-term, under 30 days). Reconstituted: refrigerate at 2-8°C and use within 28-30 days. Protect from light. Do not freeze reconstituted solution. |
Synergistic Compounds
The following compounds have been studied alongside BPC-157 + TB-500 Stack for potential complementary or synergistic effects:
Learn More
References & Further Reading
Latest News & Research
View all articles →
FDA PCAC July 2026: What the BPC-157 peptide compounding review really means
FDA’s Pharmacy Compounding Advisory Committee will review seven unapproved peptides in July 2026. What that process means for BPC-157—and what it doesn’t.
FDA signals enforcement against unapproved compounded GLP-1 drugs: what it means for peptide medicine
The FDA says it will restrict GLP-1 APIs used in mass-marketed unapproved compounded drugs and crack down on advertising that calls them generic versions of branded drugs.
Sublingual compounded peptides: Quicksome claims and what the FDA’s July 2026 PCAC review could change
A press release claims needle-free, sublingual delivery for popular compounded peptides—just as the FDA's PCAC prepares a July 2026 review of seven peptides.
Pemvidutide IMPACT 48-Week MASH Data Lands At EASL 2026 Ahead Of Phase 3
Altimmune's pemvidutide hit 32.4% ELF response, 23.7% triglyceride drop, and 54.5% qFibrosis regression in 212-patient F2/F3 MASH IMPACT Phase 2b at EASL 2026.